{"id":4666,"date":"2026-05-06T09:04:29","date_gmt":"2026-05-06T07:04:29","guid":{"rendered":"https:\/\/ksbbiotech.com\/?page_id=4666"},"modified":"2026-05-31T23:44:45","modified_gmt":"2026-05-31T21:44:45","slug":"fpsa","status":"publish","type":"page","link":"https:\/\/ksbbiotech.com\/zh\/fpsa\/","title":{"rendered":"\u6e38\u79bb\u524d\u5217\u817a\u7279\u5f02\u6027\u6297\u539f\uff08fPSA\uff09"},"content":{"rendered":"\t\t
PDB ID: 3QUM. Source: RCSB Protein Data Bank<\/span><\/span>. For illustration purposes only.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t The VeriGoldTM<\/sup> Free Prostate-Specific Antigen (fPSA) Rapid Test is a chromatographic immunoassay developed for the quantitative detection of free prostate-specific antigen (fPSA) in human serum or plasma. The assay is intended for professional in-vitro diagnostic use in clinical laboratories, healthcare facilities, and physician offices. By providing rapid and convenient measurement of fPSA levels, the test supports timely patient evaluation in point-of-care settings.<\/p> Free PSA testing, when used in combination with total PSA measurement, serves as a valuable tool for supporting prostate cancer screening and clinical assessment in adult male patients. The ratio between free PSA and total PSA may help improve differentiation between benign prostate conditions and prostate cancer. Test results should always be interpreted together with clinical findings and other diagnostic procedures.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\tVeriGoldTM<\/sup> fPSA<\/h2>\t\t\t\t<\/div>\n\t\t\t\t